Enrique Ocio, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, explains the recovery of polyclonal immunoglobulins as a predictive factor of increased progression-free survival and overall survival in patients with multiple myeloma that are ineligible for autologous stem-cell transplantation. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.